ACH
NKTR icon

ArrowMark Colorado Holdings’s Nektar Therapeutics NKTR Stock Holding History

ArrowMark Colorado Holdings’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-7,289
Closed -$3.89M – 334
2019
Q2 		$3.89M Sell
7,289
-6,333
-46% -$3.18M 0.04% 216
2019
Q1 		$6.87M Sell
13,622
-2,867
-17% -$1.7M 0.06% 192
2018
Q4 		$8.13M Buy
16,489
+3,334
+25% +$2.01M 0.09% 193
2018
Q3 		$12M Buy
13,155
+22
+0.2% +$18.8K 0.1% 181
2018
Q2 		$9.62M Sell
13,133
-52
-0.4% -$60K 0.09% 194
2018
Q1 		$21M Sell
13,185
-15,533
-54% -$20M 0.21% 115
2017
Q4 		$25.7M Sell
28,718
-1,882
-6% -$1.11M 0.26% 100
2017
Q3 		$11M Hold
30,600
– – 0.13% 152
2017
Q2 		$8.97M Buy
30,600
+4,000
+15% +$1.16M 0.11% 158
2017
Q1 		$9.36M Sell
26,600
-1,873
-7% -$421K 0.13% 138
2016
Q4 		$5.24M Hold
28,473
– – 0.08% 183
2016
Q3 		$7.34M Sell
28,473
-4,187
-13% -$1.08M 0.13% 143
2016
Q2 		$6.97M Hold
32,660
– – 0.14% 137
2016
Q1 		$6.74M Buy
32,660
+6,133
+23% +$1.18M 0.15% 127
2015
Q4 		$6.71M Hold
26,527
– – 0.18% 126
2015
Q3 		$4.36M Buy
26,527
+2,200
+9% +$389K 0.12% 153
2015
Q2 		$4.57M Hold
24,327
– – 0.11% 156
2015
Q1 		$4.01M Buy
24,327
+23,174
+2,010% +$4.76M 0.1% 150
2014
Q4 		$268K Hold
1,153
– – 0.01% 251
2014
Q3 		$209K Hold
1,153
– – 0.01% 284
2014
Q2 		$222K Hold
1,153
– – 0.01% 304
2014
Q1 		$210K Hold
1,153
– – 0.01% 286
2013
Q4 		$196K Sell
1,153
-1,460
-56% -$235K 0.01% 295
2013
Q3 		$409K Buy
2,613
+1,460
+127% +$270K 0.01% 261
2013
Q2 		$200K Buy
+1,153
New +$177K 0.05% 124

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ArrowMark Colorado Holdings's NKTR Position: Q3 2019 in Review

ArrowMark Colorado Holdings sold out of Nektar Therapeutics (NKTR) in Q3 2019, closing a stake of 7,289 shares — an estimated $3.89M sold.

ArrowMark Colorado Holdings first reported a position in NKTR in Q2 2013 and held it in 25 quarters. The position peaked at $25.7M in Q4 2017. 287 funds tracked by Wall St. Rank hold NKTR as of Q3 2019.

  • ArrowMark Colorado Holdings reported no remaining Nektar Therapeutics position as of Q3 2019 after selling out during the quarter.
  • ArrowMark Colorado Holdings sold 7,289 Nektar Therapeutics shares in Q3 2019, an estimated $3.89M.
  • ArrowMark Colorado Holdings first reported a position in Nektar Therapeutics in Q2 2013 and held it in 25 quarters.
  • ArrowMark Colorado Holdings's Nektar Therapeutics position peaked at $25.7M in Q4 2017.
  • 287 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2019.

Based on ArrowMark Colorado Holdings's 13F filing for Q3 2019, filed 14 Nov 2019.